DEVELOPMENT PIPELINE
2 ~ 3 Million
Current FAD patient population
160 Million
Individuals globally living with inherited diseases where our technology holds potential
Editact Therapeutics is advancing a genome editing pipeline designed to correct underlying genetic causes of inherited diseases. Our programs focus on disorders where existing treatments are limited to symptom management.
By targeting the genetic cause of the disease through our proprietary ‘one-for-many’ platform, we aim to deliver long lasting, transformative therapies that achieve true genetic cures.
| Program | Indication | Target Gene | Hit-to-Lead | Proof of Concept | Preclinical | IND Approval | Clinical Phase 1 |
|---|---|---|---|---|---|---|---|
| ED001 | Familial Alzheimer’s Disease | APP |
|
|
|
|
|
| ED002 | Familial Alzheimer’s Disease | PSEN1 |
|
|
|
|
|
| ED003 | Alexander Disease | GFAP |
|
|
|
|
|
| ED005 | Undisclosed | – |
|
|
|
|
|
Program
ED001
Familial Alzheimer’s Disease
Target Gene :
APP
Status:
Preclinical
|
|
|
|
|
|
Next:
IND Approval
Program
ED002
Familial Alzheimer’s Disease
Target Gene :
PSEN1
Status:
Proof of Concept
|
|
|
|
|
|
Next:
Preclinical
Program
ED003
Alexander Disease
Target Gene :
GFAP
Status:
Hit-to-Lead
|
|
|
|
|
|
Next:
Proof of Concept
Program
ED005
Undisclosed
Target Gene :
–
Status:
Target Gene
|
|
|
|
|
|
Next:
Hit-to-Lead